May 16th 2024
VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.
Payers Reveal Most Significant Factors Impacting Biosimilar Coverage Decisions
July 3rd 2023It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.